Effects of Interferon-Alpha on Rhesus Monkeys: A Nonhuman Primate Model of Cytokine-Induced Depression

Kirkwood, 1990, Role of interferons in the therapy of melanoma, J Invest Dermatol, 95, 180S, 10.1111/1523-1747.ep12875497 Saracco, 2003, Therapy of chronic hepatitis C: a critical review, Curr Drug Targets Infect Disord, 3, 25, 10.2174/1568005033342127 Hauser, 2002, A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C, Mol Psychiatry, 7, 942, 10.1038/sj.mp.4001119 Kraus, 2003, Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy, J Clin Psychiatry, 64, 708, 10.4088/JCP.v64n0614 Musselman, 2001, Paroxetine for the prevention of depression induced by high-dose interferon alfa, N Engl J Med, 344, 961, 10.1056/NEJM200103293441303 Pariante, 1999, Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders, Lancet, 354, 131, 10.1016/S0140-6736(98)04793-X Raison, 2005, Depression during pegylated interferon-alpha plus ribavirin therapy: Prevalence and prediction, J Clin Psychiatry, 66, 41, 10.4088/JCP.v66n0106 Capuron, 2003, Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy, Am J Psychiatry, 160, 1342, 10.1176/appi.ajp.160.7.1342 Gisslinger, 1993, Interferon-alpha stimulates the hypothalamic–pituitary–adrenal axis in vivo and in vitro, Neuroendocrinol, 57, 489, 10.1159/000126396 Raber, 1997, Interferon-alpha and transforming growth factor-beta 1 regulate corticotropin-releasing factor release from the amygdala: Comparison with the hypothalamic response, Neurochem Int, 30, 455, 10.1016/S0197-0186(96)00082-4 Shimizu, 1995, Increase in serum interleukin-6, plasma ACTH and serum cortisol levels after systemic interferon-alpha administration, Endocr J, 42, 551, 10.1507/endocrj.42.551 Kumai, 2000, Effect of interferon-alpha on tyrosine hydroxylase and catecholamine levels in the brain of rats, Life Sci, 67, 663, 10.1016/S0024-3205(00)00660-3 Shuto, 1997, Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain, Brain Res, 747, 348, 10.1016/S0006-8993(96)01371-6 Kamata, 2000, Effect of single intracerebroventricular injection of alpha-interferon on monoamine concentrations in the rat brain, Eur Neuropsychopharmacol, 10, 129, 10.1016/S0924-977X(99)00067-X Kitagami, 2003, Mechanism of systemically injected interferon-alpha impeding monoamine biosynthesis in rats: Role of nitric oxide as a signal crossing the blood-brain barrier, Brain Res, 978, 104, 10.1016/S0006-8993(03)02776-8 Capuron, 2003, Interferon-alpha-induced changes in tryptophan metabolism, Biol Psychiatry, 54, 906, 10.1016/S0006-3223(03)00173-2 Zhu, 2006, The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters, Neuropsychopharmacol, 31, 2121, 10.1038/sj.npp.1301029 Sanchez MM, Alagbe O, Felger JC, Zhang J, Graff AE, Grand AP, et al. (in press): Activated p38 MAPK is associated with decreased CSF 5-HIAA and increased maternal rejection during infancy in young adult rhesus monkeys. Mol Psychiatry. Ho, 1992, Opioid-dopaminergic mechanisms in the potentiation of d-amphetamine discrimination by interferon-alpha, Pharmacol Biochem Behav, 42, 57, 10.1016/0091-3057(92)90446-M Schaefer, 2003, Neurotransmitter changes by interferon-alpha and therapeutic implications, Pharmacopsychiatry, 36, S203 Wang, 2006, mu- but not delta- and kappa-opioid receptor mediates the nucleus submedius interferon-alpha-evoked antinociception in the rat, Neurosci Lett, 397, 254, 10.1016/j.neulet.2005.12.046 Reite, 1987, Interferon decreases REM latency, Biol Psychiatry, 22, 104, 10.1016/0006-3223(87)90136-3 Capuron, 2002, Neurobehavioral effects of interferon-alpha in cancer patients: Phenomenology and paroxetine responsiveness of symptom dimensions, Neuropsychopharmacol, 26, 643, 10.1016/S0893-133X(01)00407-9 Altmann, 1962, A field study of the sociobiology of rhesus monkeys, Macaca mulatta, Ann N Y Acad Sci, 102, 338, 10.1111/j.1749-6632.1962.tb13650.x Kalin, 2003, Nonhuman primate studies of fear, anxiety, and temperament and the role of benzodiazepine receptors and GABA systems, J Clin Psychiatry, 64, 41 Schino, 1996, Primate displacement activities as an ethopharmacological model of anxiety, Anxiety, 2, 186, 10.1002/(SICI)1522-7154(1996)2:4<186::AID-ANXI5>3.0.CO;2-M Troisi, 2002, Displacement activities as a behavioral measure of stress in nonhuman primates and human subjects, Stress, 5, 47, 10.1080/102538902900012378 Troisi, 1991, Scratching as a behavioral index of anxiety in macaque mothers, Behav Neural Biol, 56, 307, 10.1016/0163-1047(91)90469-7 McKinney, 1971, Effects of reserpine on the social behavior of rhesus monkeys, Dis Nerv Syst, 32, 735 Strome, 2002, Intracerebroventricular corticotropin-releasing factor increases limbic glucose metabolism and has social context-dependent behavioral effects in nonhuman primates, Proc Natl Acad Sci U S A, 99, 15749, 10.1073/pnas.232480899 Kalin, 1985, Behavioral effects of ovine corticotropin-releasing factor administered to rhesus monkeys, Fed Proc, 44, 249 Rosenzweig-Lipson, 1994, Observational studies of dopamine D1 and D2 agonists in squirrel monkeys, Psychopharmacol (Berl), 116, 9, 10.1007/BF02244865 Maestripieri, 2006, Early maternal rejection affects the development of monoaminergic systems and adult abusive parenting in rhesus macaques (Macaca mulatta), Behav Neurosci, 120, 1017, 10.1037/0735-7044.120.5.1017 Maestripieri, 2006, Influence of parenting style on the offspring’s behaviour and CSF monoamine metabolite levels in crossfostered and noncrossfostered female rhesus macaques, Behav Brain Res, 175, 90, 10.1016/j.bbr.2006.08.002 Broadbear, 2004, Corticotropin-releasing hormone antagonists, astressin B and antalarmin: Differing profiles of activity in rhesus monkeys, Neuropsychopharmacol, 29, 1112, 10.1038/sj.npp.1300410 Kalin, 2004, The role of the central nucleus of the amygdala in mediating fear and anxiety in the primate, J Neurosci, 24, 5506, 10.1523/JNEUROSCI.0292-04.2004 Reyes, 1998, The proinflammatory cytokine network: Interactions in the CNS and blood of rhesus monkeys, Am J Physiol, 274, R139 Willette, 2007, Environmental context differentially affects behavioral, leukocyte, cortisol, and interleukin-6 responses to low doses of endotoxin in the rhesus monkey Xiao, 2003, Leptin modulates inflammatory cytokine and neuroendocrine responses to endotoxin in the primate, Endocrinol, 144, 4350, 10.1210/en.2003-0532 Villinger, 1995, Comparative sequence analysis of cytokine genes from human and nonhuman primates, J Immunol, 155, 3946, 10.4049/jimmunol.155.8.3946 Wightman, 1977, Liquid chromatographic monitoring of CSF metabolites, Brain Res, 131, 345, 10.1016/0006-8993(77)90526-1 Kalin, 1987, A diurnal rhythm in cerebrospinal fluid corticotrophin-releasing hormone different from the rhythm of pituitary-adrenal activity, Brain Res, 426, 385, 10.1016/0006-8993(87)90894-8 Song, 2006, The comparison of changes in behavior, neurochemistry, endocrine, and immune functions after different routes, doses and durations of administrations of IL-1beta in rats, Pharmacopsychiatry, 39, 88, 10.1055/s-2006-941557 Anisman, 1999, Anhedonic and anxiogenic effects of cytokine exposure, Adv Exp Med Biol, 461, 199, 10.1007/978-0-585-37970-8_12 Makino, 1998, Enhancement of immobility in mouse forced swimming test by treatment with human interferon, Eur J Pharmacol, 356, 1, 10.1016/S0014-2999(98)00474-9 Sammut, 2001, Acute interferon-alpha administration modulates sucrose consumption in the rat, Psychoneuroendocrinol, 26, 261, 10.1016/S0306-4530(00)00051-2 Zalcman, 1998, Interleukin-2 and −6 induce behavioral-activating effects in mice, Brain Res, 811, 111, 10.1016/S0006-8993(98)00904-4 Dantzer, 2002, Cytokines and depression: An update, Brain Behav Immun, 16, 501, 10.1016/S0889-1591(02)00002-8 Collins, 1985, Plasma and cerebrospinal fluid pharmacokinetics of recombinant interferon alpha A in monkeys: Comparison of intravenous, intramuscular, and intraventricular delivery, Cancer Drug Deliv, 2, 247, 10.1089/cdd.1985.2.247 Greig, 1988, Plasma and tissue pharmacokinetics of human interferon-alpha in the rat after its intravenous administration, J Pharmacol Exp Ther, 245, 574 Cassidy, 2002, Acute effects of low-dose interferon-alpha on serum cortisol and plasma interleukin-6, J Psychopharmacol, 16, 230, 10.1177/026988110201600307 Sissolak, 1992, Effects of interferon-alpha (IFN) on the expression of interleukin 1-beta (IL-1), interleukin 6 (IL-6), granulocyte-macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor-alpha (TNF) in acute myeloid leukemia (AML) blasts, Leukemia, 6, 1155 Taylor, 1998, The effects of interferon-alpha on the production and action of other cytokines, Semin Oncol, 25, 23 Sunami, 2000, Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha, Clin Neuropharmacol, 23, 59, 10.1097/00002826-200001000-00012 McGinty, 1999, Regulation of neurotransmitter interactions in the ventral striatum, Ann N Y Acad Sci, 877, 129, 10.1111/j.1749-6632.1999.tb09265.x Heim, 2001, Altered pituitary-adrenal axis responses to provocative challenge tests in adult survivors of childhood abuse, Am J Psychiatry, 158, 575, 10.1176/appi.ajp.158.4.575 Cohen, 1988 Breinig, 1982, Effect of prolonged administration of interferon-alpha on pharmacokinetics, fever, lymphocyte proliferative response, and NK cell activity, J Interferon Res, 2, 195, 10.1089/jir.1982.2.195